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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S27efﬁcacy for treating pain in osteoarthritis (OA) clinical trials. Fur-
thermore, we determined the effect of glucosamine on pain in OA and
how the aforementioned factors play a role in regards to the efﬁcacy of
the preparation on pain in OA.
Methods: A systematic review and stratiﬁed meta-analysis of
randomized placebo-controlled trials (RCTs) were conducted.
Inclusion criteria consisted of RCTs testing glucosamine compounds
vs. placebo in humans with combined treatment regimens as an
exclusion criterion (i.e. glucosamine combined with other inter-
vention vs. placebo). Random effects models were applied with
inconsistency (I-squared) and heterogeneity (Tau-squared) using
Review Manager and SAS, respectively. The major outcome measure
was reduction of pain. Selecting outcome-measuring scale for data
extraction was done after a predeﬁned veriﬁed hierarchy of pain
scales; the standardized mean difference (SMD and [95%CI]) served
as effect size.
Results: The inclusion criteria yielded 25 trials (3,458 patients). Com-
pared with a placebo, glucosamine reduced pain (SMD ¼ -0.51 [-0.72 to
-0.30]), although expected high level of between-trial inconsistency
was observed (I-sq¼88%). The single most important explanation (i.e.,
covariate) was brand (reducing heterogeneity by 41%, p¼(0.00032):
Twelve trials (1,437) using the RottapharmjMadaus product apparently
resulted in signiﬁcant pain reduction (-1.05 [-1.43 to -0.68],), with a
large amount of inconsistency(I-sq¼92%); whereas 13 trials (1,963
patients) using non-RottapharmjMadaus products consistently failed to
show a reduction in pain when compared with placebo (-0.11 [-0.46 to
0.24], I-sq¼10%) - Tau-sq reduced from 0.601 to 0.359 (p<0.001). The
second most important explanation was overall risk of bias (reducing
Tau-sq by 32%).
Conclusions: Trials using the RottapharmjMadaus glucosamine prod-
uct had a superior outcome on pain in OA compared to other prepara-
tions of glucosamine, though RottapharmjMadaus trial showed large
inconsistency in their results and therefore conﬁdence in the results in
limited. We did not ﬁnd an effect of other brands of glucosamine. Most
of the observed heterogeneity in trials on glucosamine for (OA) can be
explained by brand and risk of bias.Stratiﬁed meta-analysis
Variable Trials Effect
size
95%CI tau-squared p-value for
interaction
All trials 25 0.58 (0.90 to 0.26) 0.601
Label: 0.359 0.00032
Other label 13 0.11 (0.46 to 0.24)
Rottapharmj
Madaus
12 1.05 (1.43 to 0.68)
Chemical
structure:
0.5467 0.082
HCl 4 0.03 (0.72 to 0.77)
SO4 21 -0.7 (1.04 to 0.36)
Risk of bias
(overall)
0.4079 0.004
Low RoB 8 0.09 (0.54 to 0.36)
Unclear RoB 7 0.39 (0.90 to 0.12)
High RoB 10 1.14 (1.59 to 0.69)
Industry
funding
0.5499 0.0767
Yes 14 0.83 (0.41 to 1.24)
No 11 0.26 (0.73 to 0.20)
Figure 1. Chondrogenic potential of lenti-miR-im6 transduced BMSCs.
(A) Expression pattern of miR-im6 in presence of PTHrP for chondrogenic
differentiation. (B) Transduction efﬁciency of the produced miR-im6
lentivirus in BMSCs. (C) Ratio of GAG/DNA measured in cultured lentiviral
transduced pellets after 4 weeks of culture. The bars represent means 
SD. CM: BMSCs treated with their respective chondrogenic medium. CMT:
BMSCs treated with chondrogenic medium containing 5 ng/ml TGF-b.
CMTP: BMSCs treated with chondrogenic medium containing 5 ng/ml
TGF-b and 100 ng/ml PTHrP (D and F) Gross appearances and Safranin-O
staining of each chondrogenic pellet. (E) Protein expression of chondro-
genic differentiation and hypertrophic markers in the lentiviral trans-
duced pellets. Detection of type II collagen, SOX9, ALP, and type X collagen40
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HYPERTROPHY OF DIFFERENTIATED CHONDROCYTE FROM MSC
G.-I. Im, J.-M. Lee, J.-M. Ahn, E.-A. Kim. Dongguk Univ. Ilsan Hosp.,
Goyang, REPUBLIC OF.KOREA
Purpose: To investigate that novel microRNA, miR-im6 can increase the
chondrogenic potential and inhibit the hypertrophy of BMSC through
down-regulation of transcription factor SPB-X.
Methods: Chondrogenesis of PTHrP-treated BMSCs: To induce chon-
drogenesis, in vitro pellet cultures were carried out using 2.5 105 cells
BMSCs at passage 3 in chondrogenic medium (CM); 10 ng/ml of TGF-b3
was also added for CM. From the 14th day of culture, subsets of pellets
were additionally treated with 100 ng/ml PTHrP, and after two furtherweeks of in vitro culture in their respective media, pellets were har-
vested for analysis.
Lenti-viral transduction: Lenti-viral transduction was performed by
infection of miR-im6 virus supernatant (MOI¼10) for 7 hrs on BMSCs at
passage 3. And then, they were induced chondrogenesis in the presence
of TGF-b3 for 4 weeks. Chondrogenic potentials of each pellet were
evaluated using Rq-PCR and Western blotting.
3’-UTR luciferase activity analysis: We constructed luciferase reporter
vectors harboring wild type andmutated 3’UTR of miR-im6 target genes
(SPB-X and WNT6). Luciferase reporter gene expression was inves-
tigated in Hela cell line transfected with 50 nM negative or miR-im6
mimic. Hela cells were co-transfected with each reporter vectors and
miR-im6-mimic for 24hr. And then, their proteins were extracted with
cell lysis buffer and luciferase activities were detected with
luminometer.
Analysis of chondrogenic potentials of MSC derived from SPB-X K/O
mouse: Mouse MSCs were isolated from wild type and SPB-X K/O
mouse, respectively. After their chondrogenic induction, the expression
of hedgehog related signals was compared with each other.
Results: Overexpression of miR-im6 enhances the chondrogenic
potential and inhibits hypertrophy of hBMSCs: Amount of GAG/DNA
measured in cultured lentiviral transduced pellets after 4 weeks of
culture. GAG/DNA content of lenti-miR-im6 transduced hBMSCs was
higher than other groups in treatment of TGF-b (Fig 2c). In safranin-O
staining of each chondrogenic hBMSC pellet, staining intensity of lenti-
miR-im6 transduced hBMSCs was also stronger than TGF-b treated
positive control, like PTHrP-treated positive control (Fig 2f). These
results were conﬁrmed because overexpression of miR-im6 in chon-
drogenic induction of hBMSCs enhances the expressions of chondro-
genic markers (Type II collagen, SOX9) and suppress the expression of
hypertrophic markers (ALP, Type X collagen) (Fig 2e).
MiR-im6 inhibits major molecules of hedgehog signal and wnt
signal pathway: We conﬁrmed mRNA and protein levels using Rq-PCR
and Western blotting when miR-im6 was overexpressed in hBMSCs
chondrogenic pellets after 4 weeks. Rq-PCR results show that Ihh and
ptch1 initiating hedgehog signal pathway were down regulated with
SPB-X, simultaneously (Fig 2a). Their protein levels were decreased inat 4 week after chondrogenic differentiation using Western blotting.
Figure 2. Expression pattern of major signals by SPB-X down- or up-
regulation in hBMSCs. (A and B) Genes and proteins expression in lenti-
im6 transduced hBMSCs. (C) Construct of SPB-X overexpression vector. (D)
Fluorescent microscopy of hSPB-X overexpressed BMSCs. (E and F) Rq-PCR
and Western blotting results of hSPB-X overexpressed BMSCs.
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conﬁrmed that the down-regulation of hedgehog signals by miR-im6
can suppress expression of wnt signal molecules (Wnt3a, Wnt7a,
Wnt6, Wnt9b and b-catenin)(Fig 2b). On the contrary, indian hedgehog
was transiently up-regulated by overexpression of SPB-X in hBMSCs
(Fig 2c-f).
Transcription factor SPB-X and Wnt6 are target genes of hsa-miR-
im6: As shown in Fig 3c, luciferase activitieswere signiﬁcantly decreased
in Hela cells was co-transfected with luciferase reporter vectors harbor-
ing SPB-X or WNT6 3’UTR and hsa-miR-im6 mimic. This result demon-
strates that SPB-X and WNT6 are target genes of hsa-miR-im6.
SPB-X knockout induce down-regulation of indian hedgehog: We
investigated SPB K/O effects using mouse MSCs isolated from SPB K/OFigure 4. Effect of SPB-X knockout in chondrogenic differentiation of
mouse MSCs. (A) Ratio of GAG/DNAmeasured in mouse MSC pellets after 3
weeks of culture. (B)Gross appearance ofmouseMSCs chondrogenic pellets.
(C) Protein expression of major hedgehog signal molecules, chondrogenic
differentiation and hypertrophic markers in mouse MSCs chondrogenic
pellets. (D) Blocking mechanism of chondrocyte hypertrophy by miR-im6.mouse. GAG/DNA ratio and safranin-O staining results show that
chondrogenic potentials of SPB K/O MSC is similar to that of wild
type MSC (Fig 4a and b). However, we conﬁrmed that expressions of
IHH, PTCH1, WNT6 and WNT9b were suppressed in chondrogenic
pellet of SPB K/O MSC when compared with that of wild type MSC
(Fig 4c).
Conclusions: Our results show that miR-im6 acts as a positive regulator
of chondrogenic differentiation as well as a hypertrophy blocker in
BMSCs by direct decreasing the transcription factor SBP-X and WNT
expression in PTHrP-IHH negative feedback inhibition pathway (Fig 4d).
Also, SBP-X is major transcription factor regulating indian hedgehog
protein inMSC chondrogenesis. To our knowledge, this is the ﬁrst report
showing that a speciﬁc microRNA, miR-im6, plays a crucial role in the
course of chondrogenesis.
41
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Purpose: Lower back pain (LBP) is the #1 global cause for years lived
with disability, where 80% of the population will develop LBP at some
stage of their lifetime, leading to substantial socioeconomic impact.
Intervertebral disc degeneration (IVDD) is implicated in 40% of LBP.
Current options for IVDD treatment includes surgical intervention
(spinal fusion, disc replacement) or palliative care, but there are no
available disease modifying treatments. Recent studies demonstrated
great promise with mesenchymal stem cell (MSC) therapy in IVDD,
however pre-clinical studies were restricted to small animal (rodent)
models which are not representative of human disease. We have pre-
viously developed a large animal model of ovine IVDD which repro-
duces many of the pathological features of human disease, and used this
to assess the efﬁcacy of bone marrow derived mesenchymal stem cells
(BMMSCs) for the treatment of IVDD.
Methods: A single pool of heterologous ovine BMMSCswas isolated and
culture expanded up to passage 8 for subsequent injections (Fig 1A).
These BMMSCs were capable of adipogenic, osteogenic and chondro-
genic differentiation. IVD lesion was induced by a 6 x 20mm annularFigure 1. Experimental design.Ă
